Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tirofiban for Stroke Recurrence Prevention (CHANCE-4)
NCT06319846Phase 3Recruiting
- Sponsor
- Beijing Tiantan Hospital
- Start
- Jul 2024
- Primary completion
- Oct 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tirofiban in ischemic stroke, Transient Ischemic Attack (TIA), sponsored by Beijing Tiantan Hospital. Started Jul 2024; status: recruiting.
02
Drugs
tirofiban
03
Conditions
ischemic strokeTransient Ischemic Attack (TIA)
Beyond the preview
Go deeper on NCT06319846.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06319846.